Clozapine - CAS 5786-21-0
Catalog number: 5786-21-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Dopamine Receptor
Clozapine is an atypical antipsychotic drug by acting as a 5-HT antagonist, used in the treatment of schizophrenia.
HF 1854, LX 100-129
Canonical SMILES:
1.Very Low Dose Amitriptyline for Clozapine-Associated Sialorrhea.
Sinha S1, Simlai J2, Praharaj SK3. Curr Drug Saf. 2016 Apr 26. [Epub ahead of print]
Clozapine is the antipsychotic of choice for resistant schizophrenia, but its widespread use is limited by adverse effects. Sialorrhea is a common and troublesome adverse effect seen with clozapine which leads to poor compliance. Several treatment strategies are advocated, no single treatment is considered superior. Amitriptyline, a tricyclic antidepressant, has been found to be useful for clozapine-associated sialorrhea at 87-100 mg per day. We report the effect of very low dose amitriptyline (10 mg per day) in a patient with clozapine-associated sialorrhea. There was rapid and complete resolution of sialorrhea after three days without any emergent adverse effect.
2.Use of Clozapine for Borderline Personality Disorder: A Case Report.
Amamou B1, Salah WB1, Mhalla A1, Benzarti N1, Elloumi H1, Zaafrane F1, Gaha L1. Clin Psychopharmacol Neurosci. 2016 May 31;14(2):226-8. doi: 10.9758/cpn.2016.14.2.226.
Patients with borderline personality disorder (BPD) show significant impairment in functioning, particularly in the interpersonal and social domains. Prior reports suggest that clozapine may be effective in the management of BPD. We present the case of a patient with BPD who experienced persistent suicidal ideation and was treated with clozapine at a state psychiatric hospital. After treatment failure with other psychotropic medications, clozapine medication was initiated; not only did suicidal ideation cease, but social and professional functioning also greatly improved to the point of no longer requiring intensive levels of observation or restrictive procedures. Clozapine appears to be efficacious in the management of suicide attempts and self-injurious behavior. Moreover, it appears to be promising as a therapeutic measure for ameliorating the global functioning of patients with severe BPD. Larger, randomized, blinded, and controlled prospective studies are needed to confirm these findings and to determine optimal dosage.
3.Late Onset Agranulocytosis with Clozapine Associated with HLA DR4 Responding to Treatment with Granulocyte Colony-stimulating Factor: A Case Report and Review of Literature.
Singh A1, Grover S1, Malhotra P2, Varma SC2. Clin Psychopharmacol Neurosci. 2016 May 31;14(2):212-7. doi: 10.9758/cpn.2016.14.2.212.
Agranulocytosis as a side effect of clozapine has been reported to be associated with initial phases of treatment, i.e., first six months. Agranulocytosis with clozapine during the initial phases of treatment has been linked to genetic vulnerability in the form of variations in the human leukocyte-antigen haplotypes. However, there is limited literature on late onset agranulocytosis with clozapine and this has very rarely been linked to human leukocyte-antigen haplotypes vulnerability. In this report we review the existing data on late onset agranulocytosis with clozapine and describe the case of a young man, who developed agranulocytosis with clozapine after 35 months of treatment and was found to have genetic vulnerability in form of being positive for HLA DR4. This case highlights underlying autoimmune immune mechanism in clozapine-induced agranulocytosis and the need for frequent blood count monitoring on clozapine even after the initial 6 months of starting treatment especially in patients with genetic vulnerability to develop this condition.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Dopamine Receptor Products


(CAS: 73220-03-8)

Remoxipride is a selective dopamine D2 receptor antagonist. It shows selectivity over D3 and D4 receptors with Ki values are ~ 300nM for D2 receptor, ~ 1600nM f...

CAS 1148156-63-1 ST-836

(CAS: 1148156-63-1)

ST-836, a dopamine receptor ligand, might have similar effect with dopamine and probably useful as an antiparkinsonian agent.

CAS 2376-65-0 Fluphenazine decanoate dihydrochloride

Fluphenazine decanoate dihydrochloride
(CAS: 2376-65-0)

Fluphenazine is a potent antipsychotic that acts by inhibiting dopamine receptors (Ki values 0.2 nM, 0.11 nM, and 2.0nM for D2, D3, and 5-HT2 receptors, respect...

CAS 40069-26-9 6,7-Dimethoxy-2-aminotetraline hydrobromide

6,7-Dimethoxy-2-aminotetraline hydrobrom
(CAS: 40069-26-9)

6,7-Dimethoxy-2-Aminotetraline hydrobromide is a dopamine receptor agonist.

CAS 67287-95-0 SKF 83959 hydrobromide

SKF 83959 hydrobromide
(CAS: 67287-95-0)

SKF 83959 hydrobromide is a dopamine D1-like receptor partial agonist (Ki = 1.18, 7.56, 920 and 399 nM for rat D1, D5, D2 and D3 receptors, respectively), exhib...

CAS 170858-33-0 Sonepiprazole

(CAS: 170858-33-0)

Sonepiprazole is a selective, brain penetrating and orally bioactive antagonist for the rat and human dopamine D4 receptor (Ki = 10 nM) with low affinity at oth...

CAS 67383-44-2 RU 24213

RU 24213
(CAS: 67383-44-2)

RU 24213 is a dopamine D2 receptor agonist as well as a kappa opioid receptor antagonist.

CAS 122883-93-6 Ziprasidone Hydrochloride

Ziprasidone Hydrochloride
(CAS: 122883-93-6)

The hydrochloride salt form of Ziprasidone which is an antagonism of both serotonin and dopamine receptor and could be effective against schizophrenia.

CAS 1420-55-9 thiethylperazine

(CAS: 1420-55-9)

Thiethylperazine is a dopamine receptor antagonist It is an antiemetic of the phenothiazine class. Though it was never licensed or used as an antipsychotic, it ...

CAS 104632-26-0 Pramipexole

(CAS: 104632-26-0)

Pramipexole (Mirapex) is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively.

CAS 94424-50-7 Quinagolide hydrochloride

Quinagolide hydrochloride
(CAS: 94424-50-7)

Quinagolide hydrochloride is a selective dopamine D2 receptor agonist, also is a prolactin inhibitor.

CAS 1257326-23-0 NPEC-caged-dopamine

(CAS: 1257326-23-0)

NPEC-caged-dopamine is a caged version of dopamine. It can release dopamine leading to dopamine D1 receptor activation upon UV light illumination.

CAS 182210-74-8 (S)-5-Hydroxy-DPAT hydrobromide

(S)-5-Hydroxy-DPAT hydrobromide
(CAS: 182210-74-8)

A potent and selective dopamine (DA) D2 receptor agonist.

CAS 123594-64-9 PD 128907

PD 128907
(CAS: 123594-64-9)

PD 128907 is a selective D2 and D3 dopamine receptor agonist that can be used as an antipsychotic.

CAS 146939-27-7 Ziprasidone

(CAS: 146939-27-7)

Ziprasidone is a combined 5-HT (serotonin) and dopamine receptor antagonist like other atypical antipsychotic agents. Ziprasidone targets dopamine neurotransmis...

CAS 20012-10-6 SKF 38393 hydrobromide

SKF 38393 hydrobromide
(CAS: 20012-10-6)

SKF 38393 hydrobromide is a selective dopamine D1-like receptor partial agonist (Ki = 1, ~ 0.5, ~ 150, ~ 5000 and ~ 1000 nM for D1, D5, D2, D3 and D4 receptors,...

CAS 71675-85-9 Amisulpride

(CAS: 71675-85-9)

Amisulpride is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder.

CAS 64656-40-2 3-[2-(Diproplyamino)ethyl]phenol hydrobromide

3-[2-(Diproplyamino)ethyl]phenol hydrobr
(CAS: 64656-40-2)

A dopamine receptor agonist.

CAS 179386-44-8 Sumanirole maleate

Sumanirole maleate
(CAS: 179386-44-8)

Sumanirole maleate, also referred as PNU 95666E or U95666E, is a high affinity D2 receptor full agonist that shows >200-fold selectivity over dopamine receptor ...

CAS 97548-97-5 Quinelorane hydrochloride

Quinelorane hydrochloride
(CAS: 97548-97-5)

Quinelorane hydrochloride, 2-aminopyridine analog of quinpirole, is a dopamine D2 and D3 receptor agonist (Ki= 5.7 and 3.4 nM respectively).

Chemical Structure

CAS 5786-21-0 Clozapine

Quick Inquiry

Verification code

Featured Items